Highly prioritized clinical programs
Dovitinib is a Pan-Tyrosine Kinase Inhibitor (TKI)
- Exclusively in-licensed (globally) from Novartis
- Efficacy in Phase 3 trial in Renal Cell Carcinoma (RCC) and in Phase 2 trials in 4 other cancers
- Mechanism-of-Action: Small molecule, targeted inhibitor of FGFR, VEGFR, and other RTKs
- GMP & FDA approved Drug manufacturing is completed- clinical drug supply available.
- Dovitinib DRP® is validated in 5 different cancers: RCC, GIST, liver, metastatic breast, and endometrial
- Clear Regulatory Approval Pathway- Pre-NDA meeting (U.S. FDA) for “non-inferiority” vs. Sorafenib in RCC targeted for 2020. Subsequent NDA filing for RCC with Dovitinib DRP®
- Large market potential with high unmet market need: Global RCC therapeutics market projected to grow to $6.3B by 2022. Annual sales of Nexavar® = $715 M in 2018.
2X-121 has a novel dual-inhibitory action against both PARP 1/2 and Tankyrase 1/2
- Exclusively in-licensed (globally) from Eisai.
- Efficacy in Phase 1 trial, including ovarian and pancreatic cancer
- Multi Target Mechanism-of-Action: First in class small molecule targeted inhibitor of DNA damage repair enzymes (PARP)1 and telomerase maintenance enzymes (Tankyrase).
- Multi-targeted inhibitor: PARP 1/2 and Tankyrase 1/2
- Limited drug resistance: Lack of transport by P-glycoprotein potentially overcomes resistance to PARP inhibitors
- GMP & FDA approved drug manufacturing is completed – clinical drug supply available.
- 2X-121 DRP® is validated.
- Clear Clinical Development Pathway – Phase 2 trials ongoing in ovarian cancer (Dana-Farber Cancer Institute, Boston, MA USA).
- Completion of Phase 2 trials targeted for 2021.
- Broad Combination Therapy – as mono-agent or combination with DNA damaging agents with immuno-oncology drugs
- Large market potential with high unmet market need: Global PARP market projected to reach $9Billion by 2027 use in ovarian cancer.
Ixempra® (ixabepilone) is a cell-cycle specific antimicrotubule agent. It attaches to a section of the microtubule and thereby acts on the microtubule structure and function of the cell. Oncology Venture's Ixempra study has not yet commenced.
Ixempra (US), owned by R-Pharm
- Exclusively in-licensed (Europe) from R-PHARM U.S.
- Approved in the U.S. for mBC patients.
- Mechanism-of-Action: Small molecule targeted inhibitor of microtubules (cell cytoskeleton components crucial to cell division and stability)
- GMP & FDA approved Drug manufacturing is completed – clinical drug supply available.
- IXEMPRA® DRP® is validated in metastatic breast cancer.
- Clear Clinical Development Path – Phase 2 trial front-line, neoadjuvant therapy in newly diagnosed breast cancer.
- Enrollment of Phase 2 trials targeted for 2020.
- Large market potential with high unmet market need: Global breast cancer therapeutics market projected to grow to $25Billion by 2024. Market potential for IXEMPRA® as front-line neoadjuvant therapy in newly-diagnosed breast cancer.
Other clinical programs
Oncology Venture has a wide pipeline of anti-cancer treatments. Dovitinib, 2X-121 and Ixempra® are high-priority clinical programs.
LiPlaCis, 2X-111, Irofulven and APO010 are other assets in the company's pipeline.
Enables a more targeted delivery at the tumor site of cisplatin
LiPlaCis® is a unified product consisting of the LiPlaCis drug and its DRP®, Oncology Venture’s unique companion diagnostic.
The LiPlaCis drug is an intelligent, target controlled liposome formulation of one of the world’s most widely used chemotherapeutic agents, cisplatin, which has documented efficacy in numerous tumor types.
The specific LiPlaCis formulation allows delivery of LiPlaCis directly to the tumor site where is it needed.
Glutathione-enhanced, PEGylated Liposomal Doxorubicin
2X-111 is a unified product consisting of liposomal doxorubicin and its accompanying DRP®, Oncology Venture’s unique companion diagnostic.
This novel drug candidate is designed for the liposomal delivery of the anti-cancer drug doxorubicin directly to a tumor, with a glutathione coating added to exploit active endogenous transporters, allowing the drug to cross the blood-brain barrier.
This drug candidate is a synthetic drug candidate based on a naturally occurring substance that exploits a deficiency in the DNA repair mechanism of cancer cells in a manner similar to a PARP inhibitor.
Irofulven is a unified product consisting of a synthetic drug and an accompanying DRP®, Oncology Venture’s unique companion diagnostic.
The irofulven drug alkylates DNA and protein macromolecules, forms adducts, and arrests cells in the S-phase of the cell cycle. This agent requires NADPH-dependent metabolism by alkenal/one oxidoreductase for activity.
APO010 is a novel, investigational systemic chemotherapeutic treatment targeting multiple myeloma, a systemic malignancy in the blood that affects plasma cells.
APO010 is a unified product consisting of a systemic chemotherapeutic treatment and its DRP®, Oncology Venture’s unique companion diagnostic.
The human immune system can kill cancer cells using a certain type of white blood cells called cytotoxic T lymphocytes (CTLs). One way CTLs kill cancer cells is programmed cell death (apoptosis). A Fas ligand (FasL) on the CTL binds to a death receptor (CD95) on the target cell. This triggers apoptosis.